PDCD1 and neoplasm: IHC analysis confirmed higher levels of CD8+ T cell tumor infiltrates with the combination 177Lu-FAP-2287 plus anti-PD1 on day 8 pi, with the number of CD8+ T cells increasing to 10.6% of total cells versus to 4.9% (P = 0.0018) and 6.0% (P = 0.0190) in vehicle and anti-PD-1 groups, respectively (Fig. 5A-B).